D. Western Therapeutics Institute, Inc. (4576.T)
JPY 233.0
(14.22%)
JPY 233.0
(14.22%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.09 Billion JPY | 0.99% |
| 2022 | 1.08 Billion JPY | 153.18% |
| 2021 | 427.72 Million JPY | -25.46% |
| 2020 | 573.8 Million JPY | 0.09% |
| 2019 | 573.26 Million JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 1.2 Billion JPY | 4.41% |
| 2024 Q1 | 1.15 Billion JPY | 5.94% |
| 2023 Q4 | 1.09 Billion JPY | 12.31% |
| 2023 FY | 1.09 Billion JPY | 0.99% |
| 2023 Q3 | 973.71 Million JPY | -2.59% |
| 2023 Q2 | 999.62 Million JPY | 4.89% |
| 2023 Q1 | 953.06 Million JPY | -12.16% |
| 2022 Q4 | 1.08 Billion JPY | -9.81% |
| 2022 Q3 | 1.2 Billion JPY | 0.0% |
| 2022 FY | 1.08 Billion JPY | 153.18% |
| 2021 FY | 427.72 Million JPY | -25.46% |
| 2020 FY | 573.8 Million JPY | 0.09% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 3.24 Billion JPY | 66.319% |
| PRISM BioLab Co.,LTD | 63.41 Million JPY | -1624.631% |
| GNI Group Ltd. | 26.34 Billion JPY | 95.848% |
| Linical Co., Ltd. | 10.3 Billion JPY | 89.388% |
| Trans Genic Inc. | 3.81 Billion JPY | 71.316% |
| MEDINET Co., Ltd. | 590.2 Million JPY | -85.293% |
| Soiken Holdings Inc. | 697.02 Million JPY | -56.897% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | 63.797% |
| AnGes, Inc. | 2.78 Billion JPY | 60.794% |
| OncoTherapy Science, Inc. | 513.6 Million JPY | -112.927% |
| Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 98.79% |
| Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | -209.566% |
| NanoCarrier Co., Ltd. | 1.64 Billion JPY | 33.716% |
| Carna Biosciences, Inc. | 472.35 Million JPY | -131.522% |
| CanBas Co., Ltd. | 91.98 Million JPY | -1088.857% |
| RaQualia Pharma Inc. | 809.83 Million JPY | -35.041% |
| Chiome Bioscience Inc. | 593.73 Million JPY | -84.192% |
| Kidswell Bio Corporation | 4.25 Billion JPY | 74.293% |
| PeptiDream Inc. | 29.11 Billion JPY | 96.244% |
| Oncolys BioPharma Inc. | 566.5 Million JPY | -93.046% |
| Ribomic Inc. | 155.8 Million JPY | -601.889% |
| SanBio Company Limited | 2.25 Billion JPY | 51.501% |
| Healios K.K. | 11.28 Billion JPY | 90.31% |
| BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | -335.233% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | -196.37% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | -352.845% |
| StemRIM | 187 Million JPY | -484.816% |
| CellSource Co., Ltd. | 677.73 Million JPY | -61.361% |
| FunPep Company Limited | 189.32 Million JPY | -477.637% |
| Kringle Pharma, Inc. | 596.95 Million JPY | -83.197% |
| Stella Pharma Corporation | 1.44 Billion JPY | 24.245% |
| TMS Co., Ltd. | 97.68 Million JPY | -1019.477% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | -1095.276% |
| Cuorips Inc. | 200.96 Million JPY | -444.188% |
| K Pharma,Inc. | 209.13 Million JPY | -422.921% |
| Takara Bio Inc. | 11.42 Billion JPY | 90.424% |
| ReproCELL Incorporated | 741.03 Million JPY | -47.579% |
| PhoenixBio Co., Ltd. | 917.71 Million JPY | -19.166% |
| StemCell Institute Inc. | 3.85 Billion JPY | 71.598% |
| Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | -20.384% |
| CellSeed Inc. | 301.04 Million JPY | -263.268% |